Sec Form 4 Filing - Mancini Marianna @ Viking Therapeutics, Inc. - 2023-03-28

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Mancini Marianna 2. Issuer Name and Ticker or Trading Symbol Viking Therapeutics, Inc. [ VKTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Operating Officer (Last) (First) (Middle) C/O VIKING THERAPEUTICS, INC., 9920 PACIFIC HEIGHTS BLVD, SUITE 350 3. Date of Earliest Transaction (MM/DD/YY) 03/28/2023 (Street) SAN DIEGO, CA92121 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, par value $0.00001 per share 03/28/2023 M( 1 ) 15,000 A $ 2.15 332,273 D Common Stock, par value $0.00001 per share 03/28/2023 M( 1 ) 4,873 A $ 1.88 337,146 D Common Stock, par value $0.00001 per share 03/28/2023 M( 1 ) 15,000 A $ 1.26 352,146 D Common Stock, par value $0.00001 per share 03/28/2023 M( 1 ) 53,054 A $ 1.23 405,200 D Common Stock, par value $0.00001 per share 03/28/2023 M( 1 ) 15,000 A $ 1.08 420,200 D Common Stock, par value $0.00001 per share 03/28/2023 M( 1 ) 10,000 A $ 1.04 430,200 D Common Stock, par value $0.00001 per share 03/28/2023 M ( 1 ) 24,500 A $ 4.65 454,700 D Common Stock, par value $0.00001 per share 03/28/2023 M( 1 ) 30,000 A $ 4.37 484,700 D Common Stock, par value $0.00001 per share 03/28/2023 S( 1 ) 196,563 D $ 15 288,137 D Common Stock, par value $0.00001 per share 03/29/2023 M( 1 ) 15,000 A $ 9.13 303,137 D Common Stock, par value $0.00001 per share 03/29/2023 S( 1 ) 41,242 D $ 16 261,895 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 2.15 03/28/2023 M( 1 ) 15,000 03/04/2017( 2 ) 03/04/2026 Common Stock 15,000 $ 0 0 D Stock Option (right to buy) $ 1.88 03/28/2023 M( 1 ) 4,873 03/14/2016( 3 ) 03/14/2026 Common Stock 4,873 $ 0 0 D Stock Option (right to buy) $ 1.26 03/28/2023 M( 1 ) 15,000 06/30/2017( 2 ) 06/30/2026 Common Stock 15,000 $ 0 0 D Stock Option (right to buy) $ 1.23 03/28/2023 M( 1 ) 53,054 01/05/2017( 4 ) 01/05/2027 Common Stock 53,054 $ 0 0 D Stock Option (right to buy) $ 1.08 03/28/2023 M( 1 ) 15,000 06/30/2018( 2 ) 06/30/2027 Common Stock 15,000 $ 0 0 D Stock Option (right to buy) $ 1.04 03/28/2023 M( 1 ) 10,000 08/31/2018( 2 ) 08/31/2027 Common Stock 10,000 $ 0 0 D Stock Option (right to buy) $ 4.65 03/28/2023 M( 1 ) 24,500 01/19/2019( 2 ) 01/19/2028 Common Stock 24,500 $ 0 0 D Stock Option (right to buy) $ 4.37 03/28/2023 M( 1 ) 30,000 03/30/2019( 5 ) 03/30/2028 Common Stock 30,000 $ 0 0 D Stock Option (right to buy) $ 9.13 03/29/2023 M( 1 ) 15,000 05/21/2016( 2 ) 05/21/2025 Common Stock 15,000 $ 0 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Mancini Marianna C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO, CA92121 Chief Operating Officer Signatures /s/ Michael Morneau as Attorney-in-Fact 03/30/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. ( 2 )25% of the shares subject to the option vested on each one year anniversary of the grant date. ( 3 )The shares subject to the option vested on the grant date. ( 4 )23,054 shares vested on the grant date of 01/05/2017 and 25% of the remaining 30,000 shares subject to the option vested on each one year anniversary of the grant date. ( 5 )One-third of the shares subject to the option vested on each one year anniversary of the grant date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.